Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus

Journal of Medical Virology

Volumn 82, Issue 2, 2010, Pages 263-270

  Demetriou, Victoria L ^a   Van De Vijver, David A M C ^b   Hezka, Johana ^a   Kostrikis, Leondios G ^a   Savvopoulou, Natasa ^c   Georgiades, Neoklis ^c   Charilaou, Charis C ^d   Argyriou, Argyris ^e,f   Pavlou, Tina ^g   Platritis, Kyriakos ^h   Veresies, Kyriakos L ⁱ  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Cyprus National Monitoring Centre for Drugs   (Cyprus)

^d Charilaou Biomedical Laboratory   (Cyprus)

^e Gephyra Substitution Treatment Programme   (Cyprus)

^f Anosis Detoxification Unit   (United States)

^g Aghia Skepi Therapeutic Community   (Cyprus)

^h Ploeghos Psychosocial Treatment Programme   (United States)

ⁱ Veresie Clinic   (Cyprus)

Author keywords

Core E1 region; HCV genotypes; Molecular epidemiology; NS5B region; Phylogenetic analysis

Indexed keywords

GLYCOPROTEIN E1; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NONSTRUCTURAL PROTEIN 5B; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CYPRUS; FEMALE; GENE CLUSTER; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERVIEW; INTRAVENOUS DRUG ABUSE; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; REHABILITATION CENTER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE DATABASE; TRANSACTIVATION; VIRUS STRAIN;

ADULT; CLUSTER ANALYSIS; CYPRUS; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; PREVALENCE; RISK FACTORS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; SUBSTANCE ABUSE, INTRAVENOUS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 74549193866     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21690     Document Type: Article

References (32)

1. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13:2436-2441.
2. Crofts N, Aitken CK, Kaldor JM. 1999. The force of numbers: Why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 170:220-221.
3. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, van de Vijver DA, Boucher CA, Camacho R, Vandamme AM. 2005. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797-3800.
4. Demetriou VL, van de Vijver DA, Kostrikis LG. 2009. Molecular epidemiology of hepatitis C infection in Cyprus: Evidence of polyphyletic infection. J Med Virol 81:238-248.
5. Esteban JI, Sauleda S, Quer J. 2008. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148-162.
6. Felsenstein J. 1985. Confidence limits on phylogenies: An approach using the bootstrap. Evolution 39:783-791.
7. Hagan H,Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, Flom PL. 2007. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 18:341-351.
8. Huelsenbeck JP, Ronquist F. 2001. MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics 17:754-755.
9. Kalinina O, Norder H, Mukomolov S, Magnius LO. 2002. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 76:4034-4043.
10. KimuraM. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111-120.
11. Kurbanov F, Tanaka Y, Avazova D, Khan A, Sugauchi F, Kan N, Kurbanova-Khudayberganova D, Khikmatullaeva A, Musabaev E, Mizokami M. 2008. Detection of hepatitis C virus natural recombinant RF1-2k/1b strain among intravenous drug users in Uzbekistan. Hepatol Res 38:457-464.
12. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. 2008. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 5:e50.
13. Mathei C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G, Van Damme P, Buntinx F. 2005. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: Association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis 24:514-522.
14. Moreau I, Hegarty S, Levis J, Sheehy P, Crosbie O, Kenny-Walsh E, Fanning LJ. 2006. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol J 3:95.
15. Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM. 2006. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol 78:1296-1303.
16. Oliveira Mde L, Bastos FI, Telles PR, Hacker Mde A, Oliveira SA, Miguel JC, Yoshida CF. 2009. Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and longterm injecting drug users from Rio de Janeiro, Brazil. J Clin Virol 44:200-206.
17. Peng JS, Wang X, LiuMQ, ZhouDJ, Gong J, Xu HM,Chen JP, Zhu HH, Zhou W, Ho WZ. 2008. Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China. Virus Res 135:191-196.
18. Pybus OG, CochraneA,Holmes EC, Simmonds P. 2005. The hepatitisC virus epidemic among injecting drug users. Infect Genet Evol 5:131-139.
19. Saitou N, NeiM. 1987. The neighbor-joiningmethod: A new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
20. Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. 2006. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 82:S35-S38.
21. ShepardCW,Finelli L, Alter MJ.2005. Global epidemiology ofhepatitis C virus infection. Lancet Infect Dis 5:558-567.
22. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
23. Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, Vallejo F, Suligoi B, Brugal MT, Ncube F,Wiessing L, Kretzschmar M. 2008. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: A modelling study. J Viral Hepat 15:809-816.
24. SweetingMJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, De Angelis D. 2009. Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again? Am J Epidemiol 170:352-360.
25. Sy T, Jamal MM. 2006. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 3:41-46.
26. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimagi L, Magnius LO. 2007. Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time. J Med Virol 79:374-382.
27. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEG A4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599.
28. Tan Y, Wei QH, Chen LJ, Chan PC, Lai WS, He ML, Kung HF, Lee SS. 2008.Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. PLoS ONE 3:e3608.
29. van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S. 2004. Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis. J Infect Dis 189:292-302.
30. van de Laar TJ, Langendam MW, Bruisten SM, Welp EA, Verhaest I, van Ameijden EJ, Coutinho RA, Prins M. 2005. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 77:509-518.
31. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, de Vries HJ, Mulder JW, van AgtmaelM, Jurriaans S, Wolthers KC, Coutinho RA. 2007. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 196:230-238.
32. Zhou DX, Tang JW, Chu IM, Cheung JL, Tang NL, Tam JS, Chan PK. 2006. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. J Med Virol 78:574-58